
|Articles|May 1, 2001
Steroid-sparing drugs needed to reduce risks
Dapsone, hydroxychloroquine, other agents help stem complications such as bone loss, cataracts, infections
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 2a Evaluation of Dual OX40L/TNFα Antibody Begins in HS
2
Eli Lilly Trial Shows Superior Outcomes With Ixekizumab and Tirzepatide in Patients With PsA and Obesity
3
FDA Feedback Supports BLA Pathway for Sonelokimab in HS
4
Interim Analysis Leads to Early Termination of DUPLEX-AD Study
5


















